Abstract
The epidermal growth factor receptor (EGFR/ERBB1), a prototypical tyrosine kinase receptor belonging to the ERBB family (ERBB1-ERBB4), has numerous critical roles during development, growth, and tissue homeostasis. Its essentially pro-proliferative actions are frequently exploited by tumor cells, and blocking the activity of the EGFR and of the related ERBB receptors with monoclonal antibodies or kinase inhibitors represents an important strategy for the therapy of various cancer types (1). Canonical activation of the EGFR involves binding by a ligand, induction of receptor homo- or heterodimers, phosphorylation of the intracellular kinase, and the initiation of diverse signaling pathways.
This article is protected by copyright. All rights reserved.
from #MedicinebyAlexandrosSfakianakis via xlomafota13 on Inoreader http://ift.tt/1JeRffF
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου